Evidence map›Paper›PMID 40606549›Full record

ArticleJournal of toxicologic pathology2025

Report of the AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Japan Pharmaceutical Manufacturers Association: questionnaire survey on AI pathology and utilization of whole slide image database.

Masaki Yamazaki, Emi Tomikawa, Miyoko Okada, Satoru Kajikawa, Yui Terayama, Shino Kumabe, Tetsuya Sakairi, Akira Inomata, Izumi Matsumoto, Gen Sato and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of toxicologic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Masaki YamazakiAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Emi TomikawaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Miyoko OkadaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Satoru KajikawaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Yui TerayamaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Shino KumabeAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Tetsuya SakairiAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Akira InomataAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Izumi MatsumotoAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Gen SatoAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.
Mutsumi SuzukiAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the development of Artificial Intelligence (AI) technology has led to the introduction and use of AI-based histopathological evaluation (AI pathology) by various companies and organizations. The AI Pathology Task Force of the Non-clinical Evaluation Expert Committee within the Drug Evaluation Committee of the Japan Pharmaceutical Manufacturers Association (JPMA) recognizes the importance of understanding the current use and needs surrounding AI pathology in Japan. This includes its role in non-clinical research fields, such as toxicity evaluation, drug efficacy evaluation, and basic research. In addition, assessing needs and challenges related to pathology image databases is essential. Between October and November 2023, with the cooperation of the Japanese Society of Toxicologic Pathology (JSTP), we conducted a questionnaire survey on non-clinical pathology image databases to explore these issues among JPMA-affiliated and JSTP-affiliated organizations. The questionnaire survey consisted of three items: (1) implementation and utilization of whole slide images, (2) use of AI pathology in non-clinical research fields, and (3) needs and feasibility of establishing a precompetitive pathology image database (repository) and AI pathology in the non-clinical pathology field. This report summarizes the survey results and serves as a foundation for guiding future directions in the use of AI pathology in non-clinical studies in Japan.

Indexed as

Artificial Intelligence (AI) pathologydigital pathologynon-clinicalquestionnaire survey

Identifiers

PMID40606549
PMCPMC12208863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.